Get started
Author

P. Pichler

Observed name: P Pichler
ORCID: 0000-0001-5963-2270
Observed ORCID: 0000-0001-5963-2270
OpenAlex ID: A5083154064
The influence of different peritoneal dialysis fluids on the in vitro activity of ampicillin, daptomycin, and linezolid against Enterococcus faecalis
2015 · M. Kussmann, L. Schuster, et al. · European Journal of Clinical Microbiology & Infectious Diseases · 24
Compatibility of fosfomycin with different commercial peritoneal dialysis solutions
2017 · M. Kussmann, A. Baumann, et al. · European Journal of Clinical Microbiology & Infectious Diseases · 13
PDF
Use of lipegfilgrastim for the prophylaxis of chemotherapy-induced neutropenia: Pan-European non-interventional study
2018 · G. Steger, P. Pichler, et al. · Annals of Oncology · 6
PDF
Safety and effectiveness of nab-paclitaxel in young and elderly patients with metastatic breast cancer: a prospective, multicenter non-interventional study
2016 · G. Steger, E. Petru, et al. · Annals of Oncology · 6
The AST/ALT (De Ritis) ratio predicts clinical outcome in pancreatic cancer patients treated with first-line nab-paclitaxel and gemcitabine: post-hoc analysis of an Austrian multicenter, non-interventional study
2019 · J. Riedl, F. Posch, et al. · Annals of Oncology · 4
PDF
159 | R‐pola‐glo – Chemo‐light Frontline Therapy Induces High Response Rates With a Favorable Safety Profile in Elderly/frail Patients With Aggressive Lymphoma
2025 · R. Wurm‐Kuczera, T. Melchardt, et al. · Hematological Oncology · 3
PDF
Use of lipegfilgrastim in clinical practice for the prophylaxis of chemotherapy-induced neutropenia: interim results of pan-European non-interventional study
2016 · P. Pichler, N. Claes, et al. · Annals of Oncology · 3
PDF
P15 | Randomized Comparison of Isatuximab–rd Induction Followed by Isa R Maintenance Vs. Rd Induction Followed by R Maintenance in Elderly Patients With Newly Diagnosed Multiple Myeloma (agmt Mm04 Trial)
2026 · H. Ludwig, T. Melchardt, et al. · Haematologica
PDF
Abstract PS1-11-26: Esr1 mutations and use of the oral serd elacestrant in metastatic breast cancer patients in austria: results from the agmt_mbc-registry
2026 · S. P. Gampenrieder, G. Rinnerthaler, et al. · Clinical Cancer Research
Abstract PS5-01-04: Clinical predictors for first-line treatment duration in HER2-positive metastatic breast cancer Results from the AGMT_MBC-Registry
2026 · G. Rinnerthaler, S. P. Gampenrieder, et al. · Clinical Cancer Research
Abstract PS2-04-08: Incidence of second primary tumors and second primary breast cancers events in patients with metastatic breast cancer: results from the Austrian AGMT_MBC-Registry
2026 · V. Castagnaviz, S. P. Gampenrieder, et al. · Clinical Cancer Research
321P Incidence, outcome, and biology of CNS involvement in breast cancer: Results from the Austrian AGMT_MBC-registry
2025 · S.P. Gampenrieder, V. Castagnaviz, et al. · ESMO Open
PDF
Safety and Effectiveness in R/r Cll Patients Treated With Venetoclax in Combination With Rituximab Under Real‐world Conditions in Austria, Germany, and Switzerland
2023 · I. Schwaner, H. Hebart, et al. · Hematological Oncology
PDF
283P Treatment landscape of HER2-positive metastatic breast cancer (MBC): Results from the Austrian AGMT_MBC-Registry
2021 · S.P. Gampenrieder, G. Rinnerthaler, et al. · Annals of Oncology
First‐mind: a Phase Ib, Open‐label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R‐chop in Patients With Newly Diagnosed Dlbcl
2021 · D Belada, K Kopeckova, et al. · Hematological Oncology
PDF
Austrian real world data in elderly and younger metastatic pancreatic cancer patients: Interim results of a multicenter non-interventional study with nab-paclitaxel/gemcitabine
2018 · W. Eisterer, A. Gerger, et al. · Annals of Oncology
Real-World multicenter Austrian analysis of the safety and effectiveness of nab-paclitaxel in young and elderly patients with metastatic breast cancer
2018 · G. Steger, E. Petru, et al. · European Journal of Cancer
Works count: 17
Citation count: 59
H-index: 4
I10-index: 2
Year
Topic
Type